Leadership

Bindi Chudgar is one of the most distinguished women in the corporate world. Since inception, Mrs. Chudgar’s entrepreneurial intellect has ensured that Lambda grows both organically and inorganically to become a truly global CRO. Over the years, her progressive vision and values have helped Lambda create a niche to stand apart from the rest in the CRO industry. Meticulous by nature, she overlooks Lambda’s Corporate M&A, Strategy, Finance & Human Resources embracing the best of contemporary and conventional ideologies which are the best fit for the organization globally.

Bindi’s keenness on high-quality standards is best reflected in Lambda’s exceptional regulatory track record. The organization’s various facilities across the world have undergone successful accreditations by some of the world’s topmost regulatory agencies. It is her visionary genius and strong-willed determination that helps Lambda transcend geographical boundaries to excel in the world’s most promising pharmaceutical markets, besides continually augmenting and diversifying its service portfolio and expertise.

She has always been a people’s person. She believes in building an engaging and empowering work culture which are the foundation and key drivers for building a strong and successful organization.
She is determined to continue raising the bar for the development and commercialization of new medical therapies worldwide, through Lambda.

Mr. Luke S Gill, the Chief Executive Officer of Lambda & Novum, is a seasoned leader with a remarkable track record in clinical drug development spanning over 25 years. His goal of fortifying strategic insights, fostering innovative solutions, and refining operational expertise drives the convergence of Lambda and Novum through aligned strategies and processes.

Luke holds a Neuro & Molecular Pharmacology Master’s degree and has authored numerous publications focusing on cell signaling pathways at the University of Bristol. Prior to joining our team, Luke held pivotal roles in prominent CROs such as TFS, IQVIA, PPD, and Premier Research, demonstrating leadership prowess through successful collaborations with both small and large biopharma companies. His expertise spans diverse therapeutic domains, including cell therapies, targeted small molecules, and immune-oncology, across rare indications, solid tumors, and hematological malignancies.

A strategic thinker, he excels in designing and delivering pivotal clinical studies while exhibiting a consultative approach in developing innovative solutions. Luke Gill epitomizes our commitment to excellence and innovation, driving our mission of advancing global clinical research forward.

Dr. Kammili possesses more than 25 years of combined industry experience, in Hospital and Clinical Research domains in the Health Care Industry. Dr. Kammili is ICH-GCP certified, well versed in Indian and International Regulatory guidelines applicable to Bioequivalence and Bioavailability studies, Phase 1, Phase II-IV Trials, Medical Writing, Data Management, Pharmacovigilance and Medical Imaging.

Presently, Dr. Kammili is a member on the Board of Directors and Global Head–Business Development for International (US / EU / Turkey / S.E. Asia / ROW and Emerging) markets and Indian domestic market.

He is actively involved in all M&A activities of Lambda group of companies and as a successful P&L executive, has built and managed teams to deliver stretched goals with high profitability by creating improved systems, processes and synergies within the organizations to build efficiencies, credibility and trust among the stakeholders.

Apart from the Clinical Research Domain, Dr. Kammili is also a trained Intensivist, having assisted in various Interventional Cardiac emergency procedures like Primary Angioplasties, Coronary Angiograms, and Thrombolytic therapies.

He is also a certified Basic Life Support (BLS) and Advanced Cardiac Life Support (ACLS) provider by the American Heart Association.

Gail has 23 years of experience within the science and clinical medicine fields; 20 years of that experience is with Novum. She has held a wide range of positions with increasing responsibility. In a career spanning cost analysis, project management and study conduct, she currently has a senior leadership role with Novum. Her understanding of the complexity of clinical research has helped her to direct the management and daily operations of all clinical endpoint studies and data management services. She has helped to establish the one-of-a-kind Novum Clinical Research Associate Academy. In this innovative program, clinical research associates receive structured, comprehensive training in all aspects of clinical research.

Gail is a member of the Society of Clinical Research Professionals and the Society of Clinical Research Associates.

Niraj has more than 17 years of research experience working at CROs and Pharmaceutical companies, supporting the early and late phase clinical trials. Before joining Novum, Mr. Shethji served at Sun Pharmaceuticals, Pharma Medica Research, Biovail Corp. and Watson Pharmaceuticals (currently Teva) in variety of roles and increasing responsibilities. He joined Novum in 2011 to provide scientific leadership to the talented team of scientists, technical writers, statisticians and programmers. In addition to his broad experience with the conventional oral dosage forms (solid/liquid), he gained wide-spread exposure to the design and conduct of the biostudies for complex dosage forms such as transdermal, topical (including corticosteroids), injectable, nasal/inhalation, vaginal/rectal products.

He has hands on experience in developing study designs and protocols for the NDA/ANDA/505b2 submissions, statistical evaluation/presentation of data and generating high-quality study reports. His diverse experience in fields of PK, PD, bioanalysis, biostatistics, efficacy trials and regulatory sciences assists in directing Novum team in day-to-day functions and guiding clients in their development/submission strategies. He has been greatly involved with Novum’s project management in providing the scientific and operational support to meet client’s expectations. He received his Masters of Pharmacy (Pharmacology) and BS in Pharmacy from University of Pune.

Netal has over 17 years of progressive experience in Clinical Research and Pharmaceutical domain. His research experience includes design, operations, management, strategic thinking, and business development of early and late phase studies globally.

Netal has hands-on experience conducting early and late phase clinical research Studies in various therapeutic areas including oncology, psychiatry, gastro-enterology, diabetes, skin diseases. He has extensive regulatory interaction experience with the major regulatory authorities such as USFDA, Health Canada, MHRA, ANSM, and SCC.

Netal holds MD (Pharmacology) and MBBS degrees form M S University, India. He has recently earned Global Executive MBA-Health care and life sciences from Rotman Business school, University of Toronto. He is certified clinical research professional from SOCRA (Society of Clinical Research Associates). Netal is Scientific Advisory Board Member for clinical research at York University.

David has 19 years of experience in clinical research. During this time, he has served in leadership roles throughout clinical, project management, and study management. His experience spans across many different drug delivery formulations (topical, oral, injectable, inhalation, etc.).

He has successfully managed diverse teams across different departments, both internally and externally. He is well-versed in study planning and logistics, allowing him to better serve our diverse client base.

David received his BS in Biomedical Science from Texas A&M University. Additionally, he received his Master of Business Administration and Master of Healthcare Administration from the University of Houston – Clear Lake.

Vrajesh possesses 18 years of progressive experience in the field of Finance during which he held various leadership roles serving Automobile, Foreign Trade and Pharmaceutical Research Industries.

Throughout his career, he has demonstrated a strong ability to deliver results on key business objectives with a focus on continuous improvement. Vrajesh has implemented innovative solutions that have streamlined processes and improved efficiencies for the organization. With his deep understanding of finance and accounting principles, Vrajesh brings extensive experience in FP&A (Financial planning & analysis) driving growth and creating value for the organization.

Vrajesh is qualified as a Chartered Accountant from India. He further graduated as a Chartered Professional Accountant from Canada. Vrajesh currently heads the finance team for Novum across North America.